Tisagenlecleucel Deemed Effective in Relapsed/Refractory Follicular Lymphoma
The overall response rate was 86.2%, and the complete response rate was 69.1%.
Non-Hodgkin Lymphoma
Younger Patients Who Survive Non-Hodgkin Lymphoma Face Higher Risk of Comorbidities
Researchers sought to determine the risk of comorbidities in younger patients who survive NHL compared with older patients.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
No EFS Benefit With Second-Line Tisa-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma
The median event-free survival was 3 months in both treatment arms.
Trial Testing Lonca-R in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Nivolumab Plus Chemoimmunotherapy for Primary Mediastinal B-Cell Lymphoma
This phase 3 trial is designed to test nivolumab in combination with chemoimmunotherapy in newly diagnosed primary mediastinal B-cell lymphoma.
Romidepsin Plus CHOEP Falls Short in Newly Diagnosed Peripheral T-Cell Lymphoma
Adding romidepsin to CHOEP did not improve progression-free survival in transplant-eligible, newly diagnosed peripheral T-cell lymphoma.
Pola-R-CHP Outperforms Standard Care for Diffuse Large B-Cell Lymphoma
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
Seroconversion After COVID-19 Vaccination High in CML, Low in NHL
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
Study of Combination Ibrutinib and Venetoclax in Mantle Cell Lymphoma
The study includes patients with relapsed/refractory and treatment-naïve mantle cell lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...